KẾT QUẢ ĐIỀU TRỊ UNG THƯ BÀNG QUANG CHƯA XÂM LẤN CƠ BẰNG PHẪU THUẬT CẮT ĐỐT NỘI SOI KẾT HỢP BƠM DOXORUBICIN TẠI BỆNH VIỆN ĐA KHOA TRUNG ƯƠNG CẦN THƠ

Abstract

Background: Bladder cancer is one of the most common cancer of urologic cancer. At the time of diagnosis, 60-80% cases is non-muscle invasive bladder cancer. The basic method to treat non-muscle invasive bladder cancer is transurethral resection of bladder cancer combi with intravesical after operation. In Can Tho Central General Hospital, Doxorubicin are using to inject intravesical after operation. Objectives: To evaluate result of treatment of non-muscle invasive bladder cancer by transurethral resection bladder tumor combied with doxorubicin intravesical after operation. Materials and methods: A descriptive, prospective cross-sectional study with 30 patients with non-muscle invasive bladder cancer from March 2021 to January 2023. Results: Male/Female ratio: 22/8. Mean age: 55±11.7 years old. 73.3% cases come to the hospital because of hematuria. Average operating time: 35.22±13.5 minutes. Mean hospital stay: 6.53±1.6 days. The reults: good evaluation was the highest (93.3%), no bad evaluation. Postoperative pathological results: 56.7% PTa, 43.3% PT1 and in almost cases were Grade 1 (63.3%). Probability of recurrence after 12 months is 3.8%. Conclusion: Transurethral resection of non-muscle invasive bladder cancer is safe and feasible. Doxorubicin intravesical after operation is safe, easy of implementation, no severe complication. After 12 months, the probability of recurrence is 3.8%.